New combo therapy shows promise in early trial for liver-metastatic colorectal cancer
NCT ID NCT02837263
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested the safety of combining the immunotherapy drug pembrolizumab with precise, high-dose radiation (SBRT) to the liver in 15 adults with colorectal cancer that had spread only to the liver. The goal was to see if this combination could prevent the cancer from coming back within one year after all visible tumors were surgically removed. The study focused on safety and recurrence rates, not on a cure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, 53792, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop colon polyps from coming back?
- A stitch in time: could a device make abdominal closure safer?
- Can we predict chemo brain before it happens?
- Your gut bacteria might reveal hidden cancer risk
- Can a smart digital program restore sleep for cancer survivors?
- Can a new infusion drug shrink Hard-to-Treat tumors?